Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkw439 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid viral suppression using integrase inhibitors during acute HIV-1 infection.
J Antimicrob Chemother
November 2024
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Background: Antiretroviral therapy (ART) is recommended for all individuals with HIV infection, including those with acute HIV-1 infection (AHI). While recommendations are similar to those for chronic infection, efficacy data regarding treatment of acute HIV is limited.
Methods: This was a single arm, 96-week study of a once-daily integrase inhibitor (INSTI)-based regimen using elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) in AHI.
A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China.
Lancet Reg Health West Pac
July 2023
Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Article Synopsis
- Direct-acting antiviral agents (DAAs) have significantly improved the treatment of Hepatitis C (HCV), but an effective and safe treatment for patients co-infected with HIV remains a challenge, especially in low-resource settings.
- This study evaluated the safety and efficacy of a 12-week treatment with sofosbuvir and velpatasvir in chronic HCV/HIV-1 co-infected patients who were already on an antiretroviral regimen.
- Among 243 patients in the study, 97% achieved a sustained virologic response (SVR12) after treatment, demonstrating the high effectiveness of this regimen across different HCV genotypes.
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study.
AIDS Res Ther
January 2023
Infectious Diseases Department, APHP-Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France.
Article Synopsis
- The study evaluated the effectiveness of switching HIV patients on stable antiretroviral therapy to a co-formulated drug called E/C/F/TDF, measuring success by the number of patients maintaining low viral loads at 48 weeks.
- A total of 382 patients were analyzed, showing that 82% maintained viral loads below 50 copies/mL, while only 3.5% experienced virological failure, primarily linked to past treatment issues.
- Resistance to integrase inhibitors was noted in those who failed treatment, though overall, the switch to E/C/F/TDF was well tolerated with minimal adverse effects reported.
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age.
HIV Med
January 2023
Gilead Sciences, Foster City, California, USA.
Objectives: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective treatment for HIV-1 infection; however, clinical trial data in older people living with HIV (PLWH) are lacking. The primary 24-week and secondary 48-week analyses of study GS-US-380-4449 (NCT03405935), which assessed the efficacy and safety of switching to B/F/TAF in older PLWH, have been published. Here we report the results of the final 96-week analyses from the study.
View Article and Find Full Text PDFEffectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.
Afr Health Sci
December 2021
Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine Department of Infectious Diseases and Clinical Microbiology.
Background: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (E/C/F/TDF) in treatment-naïve and experienced patients with HIV infection was demonstrated in phase 3 trials. The primary objective of this study was to evaluate effectiveness and safety of E/C/F/TDF in real world settings.
Methods: Retrospective, observational data collected by the Turkish ACTHIV-IST study group between May 2015 and December 2016 were analysed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!